Towards Healthcare

Clinical Microbiology Companies Strategic Expansion Initiatives, Revenue Diversification, Strategic Joint Ventures, Licensing and Monetization, Peer Comparison Analysis, Leadership and Governance

Date: January 2025

Clinical Microbiology Top Companies and Strategic Involvements

The global clinical microbiology market size was valued at US$ 4.61 billion in 2023 is expected to reach US$ 7.78 billion by 2033. It is poised to grow at a compound annual growth rate (CAGR) of 5.37% from 2024 to 2033.

Top Companies in the Clinical Microbiology Market

  • Thermo Fisher Scientific Inc.
  • GSK
  • BioMérieux
  • Danaher Corporation
  • Becton, Dickinson and Company
  • F. Hoffmann-La Roche Ltd
  • QIAGEN N. V
  • 3M
  • Bio-Rad Laboratories
  • Bruker Corporation
  • Hologic Inc.
  • Abbott Laboratories
  • Merck KGaA
  • Diagnóstica Longwood SL
  • Agilent Technologies Inc.
  • Memmert GmbH + Co.KG
  • Hardy Diagnostics
  • NEOGEN Corporation
  • T2 Biosystems Inc.

T2 BioSystems Inc.  Pipeline in the Clinical Microbiology Market

Company Name T2 Biosystems Inc.
Headquarters Massachusetts, U.S.
Recent Development In March 2024, T2 Biosystems, Inc., a pioneer in the quick identification of sepsis-causing bacteria and genes linked to antibiotic resistance, revealed plans for the commercial launch of the T2Lyme Panel and gave an update on recent business developments. Leading the way in the quick identification of sepsis-causing bacteria and antibiotic resistance genes, T2 Biosystems is committed to lowering healthcare costs and enhancing patient outcomes by enabling physicians to treat patients more quickly and efficiently than ever before. The Candida auris test, the T2LymeTM Panel, and the U.S. T2Resistance Panel are among the next products that T2 Biosystems is actively developing.

BioMérieux Pipeline in the Clinical Microbiology Market

Company Name Entos Pharmaceuticals
Headquarters Alberta, Canada
Recent Development In January 2024, with its Fusogenix proteolipid vehicle (PLV) nucleic acid delivery platform, Entos Pharmaceuticals, a clinical-stage biotechnology firm, is creating genetic medications. The business just opened a new GMP production facility in Carlsbad, CA. The company's pipeline of partnered and proprietary products will undergo clinical trials and IND-enabling research, with the new location supporting the in-house manufacture of therapeutic material. The plant has 20,000 square feet of area set out for manufacturing, with separate suites for the manufacture of mRNA and plasmid DNA in addition to a lipid formulation production suite. The goal of this laboratory is to assist in the clinical development of COVID-19 booster vaccines, such as Covigenix, as well as potential treatments for cancer, infectious illnesses, uncommon disorders, and eye and ophthalmic ailments.

Recent Developments

  • In February 2024, Gepotidacin, a prospective first-in-class oral antibiotic with a unique mode of action for adults and adolescents with uncomplicated urogenital gonorrhea, produced encouraging headline findings from the key EAGLE-1 phase III trial, according to GSK plc. The trial's primary effectiveness goal was achieved when oral gepotidacin (three thousand mg taken twice daily) showed no discernible difference from intramuscular (IM) ceftriaxone (five thousand mg) with oral azithromycin (one thousand mg), which is a commonly used combination therapy for gonorrhea. The outcome depends on the microbiological response's primary endpoint, which is success or failure, at the Test-of-Cure (ToC) visit, which occurs three to seven days following therapy.
  • In January 2024, the Office of Industry and Economic Partnerships at the University of Pittsburgh established a three-year research and development agreement between the University and bioMérieux, a French biotech business that is a world leader in infectious disease diagnostic technologies. The firm's analytical and sequencing team will work with experts from Pitt's Division of Clinical Microbiology and Division of Infectious Diseases on the first project, a sequencing study.
  • In March 2023, with a focus on point-of-care testing, BioMérieux executives highlighted planned product launches that are anticipated to fuel long-term development in the company's molecular, microbiology and immunoassay divisions. The sample-to-answer system will run an anticipated five-target respiratory virus panel, which includes a rhinovirus/enterovirus target and may be reimbursable in an outpatient setting. It also boasts several features tailored for the point-of-care market, such as high multiplexing and a 15-minute time for results.